Modafinil to treat fatigue in amyotrophic lateral sclerosis: An open label pilot study

Gregory T. Carter, Michael D. Weiss, Jau Shin Lou, Mark P. Jensen, R. Ted Abresch, Tara K. Martin, Thomas W. Hecht, Jay J. Han, Patrick Weydt, George H. Kraft

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

An open label trial of modafinil was conducted to determine whether it would be tolerated and effective in treating fatigue for people with amyotrophic lateral sclerosis (ALS). Fifteen patients with ALS were treated for two weeks with either 200 mg or 400 mg of modafinil. Reported side effects of the medication were mild and included diarrhea, headache, nervousness, and insomnia. Side effects did not result in any study dropouts. Following treatment, mean scores on the Fatigue Severity Scale (FSS) decreased from 51.3 (SD 9.2) to 42.8 (SD 10.2). On the Epworth Sleepiness Scale (ESS), mean scores decreased from 8.2 (SD 2.0) to 4.5 (SD 2.4). Reductions in both the FSS and the ESS were significant at p < 0.001. Mean scores on the self-report version of the Functional Independence Measure (FIM-SR) increased from 115.2 (SD 5.6) to 118.1 (SD 5.4), with p < 0.01. This pilot study suggests that modafinil is well-tolerated and may reduce symptoms of fatigue in ALS. Further blinded, controlled studies of modafinil in larger numbers of ALS patients are warranted.

Original languageEnglish (US)
Pages (from-to)55-59
Number of pages5
JournalAmerican Journal of Hospice and Palliative Medicine
Volume22
Issue number1
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Amyotrophic Lateral Sclerosis
Fatigue
Sleep Initiation and Maintenance Disorders
Self Report
Headache
Diarrhea
Anxiety
modafinil
Therapeutics

Keywords

  • Amyotrophic lateral sclerosis
  • Fatigue
  • Functional independence measure
  • Modafinil
  • Motor neuron disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carter, G. T., Weiss, M. D., Lou, J. S., Jensen, M. P., Abresch, R. T., Martin, T. K., ... Kraft, G. H. (2005). Modafinil to treat fatigue in amyotrophic lateral sclerosis: An open label pilot study. American Journal of Hospice and Palliative Medicine, 22(1), 55-59.

Modafinil to treat fatigue in amyotrophic lateral sclerosis : An open label pilot study. / Carter, Gregory T.; Weiss, Michael D.; Lou, Jau Shin; Jensen, Mark P.; Abresch, R. Ted; Martin, Tara K.; Hecht, Thomas W.; Han, Jay J.; Weydt, Patrick; Kraft, George H.

In: American Journal of Hospice and Palliative Medicine, Vol. 22, No. 1, 01.2005, p. 55-59.

Research output: Contribution to journalArticle

Carter, GT, Weiss, MD, Lou, JS, Jensen, MP, Abresch, RT, Martin, TK, Hecht, TW, Han, JJ, Weydt, P & Kraft, GH 2005, 'Modafinil to treat fatigue in amyotrophic lateral sclerosis: An open label pilot study', American Journal of Hospice and Palliative Medicine, vol. 22, no. 1, pp. 55-59.
Carter GT, Weiss MD, Lou JS, Jensen MP, Abresch RT, Martin TK et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: An open label pilot study. American Journal of Hospice and Palliative Medicine. 2005 Jan;22(1):55-59.
Carter, Gregory T. ; Weiss, Michael D. ; Lou, Jau Shin ; Jensen, Mark P. ; Abresch, R. Ted ; Martin, Tara K. ; Hecht, Thomas W. ; Han, Jay J. ; Weydt, Patrick ; Kraft, George H. / Modafinil to treat fatigue in amyotrophic lateral sclerosis : An open label pilot study. In: American Journal of Hospice and Palliative Medicine. 2005 ; Vol. 22, No. 1. pp. 55-59.
@article{9d4f7ac35814464a914c0e9e0349f050,
title = "Modafinil to treat fatigue in amyotrophic lateral sclerosis: An open label pilot study",
abstract = "An open label trial of modafinil was conducted to determine whether it would be tolerated and effective in treating fatigue for people with amyotrophic lateral sclerosis (ALS). Fifteen patients with ALS were treated for two weeks with either 200 mg or 400 mg of modafinil. Reported side effects of the medication were mild and included diarrhea, headache, nervousness, and insomnia. Side effects did not result in any study dropouts. Following treatment, mean scores on the Fatigue Severity Scale (FSS) decreased from 51.3 (SD 9.2) to 42.8 (SD 10.2). On the Epworth Sleepiness Scale (ESS), mean scores decreased from 8.2 (SD 2.0) to 4.5 (SD 2.4). Reductions in both the FSS and the ESS were significant at p < 0.001. Mean scores on the self-report version of the Functional Independence Measure (FIM-SR) increased from 115.2 (SD 5.6) to 118.1 (SD 5.4), with p < 0.01. This pilot study suggests that modafinil is well-tolerated and may reduce symptoms of fatigue in ALS. Further blinded, controlled studies of modafinil in larger numbers of ALS patients are warranted.",
keywords = "Amyotrophic lateral sclerosis, Fatigue, Functional independence measure, Modafinil, Motor neuron disease",
author = "Carter, {Gregory T.} and Weiss, {Michael D.} and Lou, {Jau Shin} and Jensen, {Mark P.} and Abresch, {R. Ted} and Martin, {Tara K.} and Hecht, {Thomas W.} and Han, {Jay J.} and Patrick Weydt and Kraft, {George H.}",
year = "2005",
month = "1",
language = "English (US)",
volume = "22",
pages = "55--59",
journal = "American Journal of Hospice and Palliative Medicine",
issn = "1049-9091",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Modafinil to treat fatigue in amyotrophic lateral sclerosis

T2 - An open label pilot study

AU - Carter, Gregory T.

AU - Weiss, Michael D.

AU - Lou, Jau Shin

AU - Jensen, Mark P.

AU - Abresch, R. Ted

AU - Martin, Tara K.

AU - Hecht, Thomas W.

AU - Han, Jay J.

AU - Weydt, Patrick

AU - Kraft, George H.

PY - 2005/1

Y1 - 2005/1

N2 - An open label trial of modafinil was conducted to determine whether it would be tolerated and effective in treating fatigue for people with amyotrophic lateral sclerosis (ALS). Fifteen patients with ALS were treated for two weeks with either 200 mg or 400 mg of modafinil. Reported side effects of the medication were mild and included diarrhea, headache, nervousness, and insomnia. Side effects did not result in any study dropouts. Following treatment, mean scores on the Fatigue Severity Scale (FSS) decreased from 51.3 (SD 9.2) to 42.8 (SD 10.2). On the Epworth Sleepiness Scale (ESS), mean scores decreased from 8.2 (SD 2.0) to 4.5 (SD 2.4). Reductions in both the FSS and the ESS were significant at p < 0.001. Mean scores on the self-report version of the Functional Independence Measure (FIM-SR) increased from 115.2 (SD 5.6) to 118.1 (SD 5.4), with p < 0.01. This pilot study suggests that modafinil is well-tolerated and may reduce symptoms of fatigue in ALS. Further blinded, controlled studies of modafinil in larger numbers of ALS patients are warranted.

AB - An open label trial of modafinil was conducted to determine whether it would be tolerated and effective in treating fatigue for people with amyotrophic lateral sclerosis (ALS). Fifteen patients with ALS were treated for two weeks with either 200 mg or 400 mg of modafinil. Reported side effects of the medication were mild and included diarrhea, headache, nervousness, and insomnia. Side effects did not result in any study dropouts. Following treatment, mean scores on the Fatigue Severity Scale (FSS) decreased from 51.3 (SD 9.2) to 42.8 (SD 10.2). On the Epworth Sleepiness Scale (ESS), mean scores decreased from 8.2 (SD 2.0) to 4.5 (SD 2.4). Reductions in both the FSS and the ESS were significant at p < 0.001. Mean scores on the self-report version of the Functional Independence Measure (FIM-SR) increased from 115.2 (SD 5.6) to 118.1 (SD 5.4), with p < 0.01. This pilot study suggests that modafinil is well-tolerated and may reduce symptoms of fatigue in ALS. Further blinded, controlled studies of modafinil in larger numbers of ALS patients are warranted.

KW - Amyotrophic lateral sclerosis

KW - Fatigue

KW - Functional independence measure

KW - Modafinil

KW - Motor neuron disease

UR - http://www.scopus.com/inward/record.url?scp=13444274616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13444274616&partnerID=8YFLogxK

M3 - Article

C2 - 15736608

AN - SCOPUS:13444274616

VL - 22

SP - 55

EP - 59

JO - American Journal of Hospice and Palliative Medicine

JF - American Journal of Hospice and Palliative Medicine

SN - 1049-9091

IS - 1

ER -